AnaptysBio Shares Rise on Strategic Restructuring and Drug Insights Announcement

AnaptysBio shares are trading higher after the company announced plans to separate its biopharma operations from substantial royalty assets by year-end 2026, along with upcoming insights into its drug ANB033, a CD122 antagonist.